Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D016403 | Lymphoma, Large B-Cell, Diffuse NIH | 1.00 |
D016393 | Lymphoma, B-Cell NIH | 0.71 |
D008223 | Lymphoma, NIH | 0.32 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012191 | B-cell lymphoma HPO | 0.71 |
HP:0002665 | Lymphoma HPO | 0.32 |
Navigate: Correlations HPO
There is one clinical trial.
This study evaluates the addition of Sintilimab to current 2nd line salvage therapy of Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). All patients will receive four cycles of sintilimab plus R-GemOx. Afterwards, 1) patients who achieve CR assessed by PET-CT and are eligible for autologous stem cell transplantation (ASCT) will undergo ASCT. After transplantation, patients will receive sintilimab monotherapy up to 8 cycles or until disease recurrence and progression, death, intolerance and toxicity, withdrawal of informed consent, or other reasons specified in the protocol. 2) Patients who achieve CR assessed by PET-CT and are not eligible for ASCT will directly receive sintilimab monotherapy as maintenance treatment for a maximum of 8 cycles as described above. 3) Patients achieved PR, SD or PD assessed by PET/CT will withdraw from this study and receive proper treatment based on investigator's decision.
Description: Complete response rate after treated by Sintilimab and R-GemOx
Measure: Complete response rate Time: 6 weeks after the last dose of the combination therapy (each cycle is 21 days)Description: Overall response rate after treated by Sintilimab and R-GemOx
Measure: Over response rate (ORR) Time: 6 weeks after the last dose of the combination therapy (each cycle is 21 days)Description: from date of inclusion to date of progression, relapse, or death from any cause
Measure: Overall Survival (OS) Time: 2 yearsDescription: All the adverse events of the patients related will be assessed and graded by NCI CTCAE v 5.0
Measure: Rate of grade 3 or 4 treatment related adverse effect Time: Time Frame: Up to 30 days after the last cycle of per-protocol treatment and 90 days after last dose of anti-PD-1 antibody (each cycle is 28 days)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports